A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Shanghai Henlius Biotech
Shanghai Henlius Biotech
Bayer
Agenus Inc.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
AstraZeneca
Hoffmann-La Roche
MediLink Therapeutics (Suzhou) Co., Ltd.
Convalife (Shanghai) Co., Ltd.
Daiichi Sankyo
Daiichi Sankyo
Sichuan Baili Pharmaceutical Co., Ltd.
ImmunityBio, Inc.
Seagen Inc.
Jiangsu HengRui Medicine Co., Ltd.
Precigen, Inc
Sichuan Baili Pharmaceutical Co., Ltd.
Merck Sharp & Dohme LLC
Iovance Biotherapeutics, Inc.
Regeneron Pharmaceuticals
Merck Sharp & Dohme LLC
Jiangsu HengRui Medicine Co., Ltd.
Telix Pharmaceuticals (Innovations) Pty Limited
BeiGene
Akeso
Akeso
Akeso
Xencor, Inc.
Tasly Biopharmaceuticals Co., Ltd.
Akeso
Rain Oncology Inc
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC
Convalife (Shanghai) Co., Ltd.
Agenus Inc.
RemeGen Co., Ltd.
Shandong New Time Pharmaceutical Co., LTD
Nykode Therapeutics ASA
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
EMD Serono
pharmaand GmbH
Seagen Inc.
Shanghai Zerun Biotechnology Co.,Ltd
Gradalis, Inc.
Hoffmann-La Roche
Karyopharm Therapeutics Inc
Beijing Health Guard Biotechnology, Inc
Qilu Pharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Henlius Biotech